Skip to content

Research

Laurent Peyrin-Biroulet Recherche

Throughout my career I have published more than 700 articles in PubMed, giving me an H-index of 72 and thus making me the top-rated expert in Crohn’s Disease (CD) in the world according to “Expertscape”. In 2019, I was amongst the most “Highly Cited Researchers” worldwide.

Before my PhD, my first interest was to generate real-world evidence data by capitalizing on the Nancy inflammatory bowel disease (IBD) cohort that I initiated in 2010. As no IBD group existed at Nancy University Hospital, I decided to start training young fellows in every field of medicine (gastroenterology, nutrition, radiology, histology etc.) to speed up IBD research locally.

Following my stay at Mayo Clinic, I had the idea to work on the first definition of early CD that was subsequently discussed during an international consensus meeting to develop the Paris definition of early CD in 2011. This new concept in the field of IBD has led many investigators worldwide to conduct clinical studies looking at the impact of early intervention on patients’ lives and disease complications.

In the early 2010s, I developed translational research by focusing on the role of nutrition in the pathogenesis of IBD at INSERM U1256 NGERE at Lorraine University. After leading the Nancy IBD group at Nancy University Hospital, I am now the head of team 2 INSERM U1256 NGERE that was created in 2019 and that combines animal and human studies, with the ultimate aim to improve the quality of care of patients with IBD. The first achievement of my team was the identification of the deleterious effects of high-sucrose diet on intestinal homeostasis in mice by causing a pre-IBD state under physiological conditions. These findings may open new therapeutic avenues for these patients based on safe and efficient diet intervention.

I have coordinated the creation of several international guidelines such as the “Selecting endpoints for disease-modification trials in inflammatory bowel disease” (STRIDE) recommendations. I am the co-founder of the Spectrum international consortium that aims at collecting all available information from the top IBD centers across the world regarding the role of therapeutic drug monitoring in these patients.

My next challenges :

  1. Short-term goal : Living a normal life with IBD.
  2. Mid-term goal : Curing IBD.
  3. Long-term goal : A world free of Immune-Mediated Inflammatory Diseases.

Major Achievements

1

Development of a new MRI imaging protocol to provide an effective alternative to endoscopy with a diffusion colo-MRI with no oral or rectal preparation and no fasting. See the article

2

Development of the Nancy Radiological Score, a highly sensitive and reliable tool for assessing treatment response and accurately identifying mucosal healing in ulcerative colitis. See the article (2018) See the article (2017)

3

Development of the first functional disability index for inflammatory bowel disease with the WHO. See the article

4

Development of the Nancy Histological Index which is the easiest and fastest histological index to use in ulcerative colitis, with good intra- and inter-observer reproducibility. The Nancy Histological Index is now used worldwide in both routine practice and phase 1-3 clinical trials. See the article

5

The ICARE project (initiated in 2010) has enrolled prospectively 10 000 IBD patients across Europe by creating a network of 503 investigators from 15 countries. This will be the first prospective longitudinal study looking at the real impact of current drugs on patients’ lives and disease courses, with the final aim at identifying the best therapeutic strategy for IBD patients. Download the ICARE newsletter

Evolution of the number of publications

Last update : 09/11/2020

2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
  • 3
  • 4
  • 9
  • 14
  • 17
  • 21
  • 27
  • 44
  • 47
  • 69
  • 56
  • 65
  • 79
  • 89
  • 72
  • 87
  • 150

10 major publications :

  • Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S; VARSITY Study Group. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. N Engl J Med. 2019;381:1215-1226.
  • Siegel CA, Whitman CB, Spiegel BMR, Feagan B, Sands B, Loftus EV Jr, Panaccione R, D’Haens G, Bernstein CN, Gearry R, Ng SC, Mantzaris GJ, Sartor B, Silverberg MS, Riddell R, Koutroubakis IE, O’Morain C, Lakatos PL, McGovern DPB, Halfvarson J, Reinisch W, Rogler G, Kruis W, Tysk C, Schreiber S, Danese S, Sandborn W, Griffiths A, Moum B, Gasche C, Pallone F, Travis S, Panes J, Colombel JF, Hanauer S, Peyrin-Biroulet L. Development of an index to define overall disease severity in IBD. Gut. 2018;67:244-254.
  • Gower-Rousseau C, Sarter H, Savoye G, Tavernier N, Fumery M, Sandborn WJ, Feagan BG, Duhamel A, Guillon-Dellac N, Colombel JF, Peyrin-Biroulet L; International Programme to Develop New Indexes for Crohn’s Disease (IPNIC) group; International Programme to Develop New Indexes for Crohn’s Disease (IPNIC) group. Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort. Gut. 2017;66:588-596.
  • Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn’s disease. Lancet. 2017;389:1741-1755.
  • Marchal-Bressenot A, Salleron J, Boulagnon-Rombi C, Bastien C, Cahn V, Cadiot G, Diebold MD, Danese S, Reinisch W, Schreiber S, Travis S, Peyrin-Biroulet L. Development and validation of the Nancy histological index for UC. Gut. 2017;66:43-49.
  • Melhem H, Hansmannel F, Bressenot A, Battaglia-Hsu SF, Billioud V, Alberto JM, Gueant JL, Peyrin-Biroulet L. Methyl-deficient diet promotes colitis and SIRT1-mediated endoplasmic reticulum stress. Gut. 2016;65:595-606.
  • Peyrin-Biroulet L, Reinisch W, Colombel JF, Mantzaris GJ, Kornbluth A, Diamond R, Rutgeerts P, Tang LK, Cornillie FJ, Sandborn WJ. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn’s disease in the SONIC trial. Gut. 2014;63:88-95.
  • Peyrin-Biroulet L, Billioud V, D’Haens G, Panaccione R, Feagan B, Panés J, Danese S, Schreiber S, Ogata H, Hibi T, Higgins PD, Beaugerie L, Chowers Y, Louis E, Steinwurz F, Reinisch W, Rutgeerts P, Colombel JF, Travis S, Sandborn WJ. Development of the Paris definition of early Crohn’s disease for disease-modification trials: results of an international expert opinion process. Am J Gastroenterol. 2012;107:1770-6.
  • Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB, Simon T, Carbonnel F, Colombel JF, Dupas JL, Godeberge P, Hugot JP, Lémann M, Nahon S, Sabaté JM, Tucat G, Beaugerie L; Cesame Study Group. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011;141:1621-28.e1-5.
  • Oussalah A, Laurent V, Bruot O, Bressenot A, Bigard MA, Régent D, Peyrin-Biroulet L. Diffusion-weighted magnetic resonance without bowel preparation for detecting colonic inflammation in inflammatory bowel disease. Gut. 2010;59:1056-65.

Have Questions ?

Contact Me Now

Phone me
Research: +33 3 83 15 36 61
Clinical: +33 3 83 15 33 54
Mail me
CHRU Nancy Brabois
Service HGE
5 Allée du Morvan
54500 Vandoeuvre-les-Nancy
France

La version de votre navigateur est obsolète et votre appareil est exposé à des risques de sécurité.

Pour profiter d'une expérience optimale sur ce site il est fortement recommandé de mettre à jour votre navigateur ou d'en installer un autre :